MedTrace Logo

Venetoclax After TKI to Target Persisting Stem Cells in CML

NCT05701215 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-03-10

No results posted yet for this study

Summary

There is currently no available treatment, capable to increase the rate of sustained deep molecular remissions after TKI discontinuation in CML. Venetoclax could be such a drug. The study will provide unprecedented biological insights on the effects of venetoclax in controlling minimal residual stem cell disease induced by long-term prior TKI therapy. If the study would be positive, the findings could become practice changing for patients in deep molecular remission under TKI and willing to tolerate a temporary additional treatment.

Conditions

  • Chronic Myeloid Leukemia

Interventions

DRUG

Venetoclax

Venetoclax will be taken orally once daily (400 mg) for 12 months

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • AbbVie

    collaborator INDUSTRY

  • Thomas Ernst, PD Dr. med.

    lead OTHER

Principal Investigators

  • Thomas Ernst, Prof. Dr. · University Hospital Jena

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05701215 on ClinicalTrials.gov